Patif Eye Drop is an ophthalmic formulation used for the treatment and management of allergic conjunctivitis and symptoms associated with ocular allergies. The preparation contains Pemirolast Potassium 0.1% w/v, an anti-allergic agent belonging to the class of mast cell stabilizers. This category of medicines works by preventing the release of chemical mediators responsible for allergic reactions in the eye. Patif is generally used in conditions where itching, redness, watering, or irritation is triggered by exposure to allergens such as dust, pollen, animal dander, or environmental irritants.

Pemirolast Potassium, the active ingredient in Patif, functions by inhibiting mast cell degranulation. Mast cells are specialized immune cells found in the conjunctiva and other tissues. When exposed to allergens, these cells release histamine and other inflammatory mediators like prostaglandins, leukotrienes, and cytokines. These substances cause itching, redness, and swelling. Pemirolast stabilizes the mast cell membrane, preventing the release of these mediators and thereby helping to control allergic symptoms. It does not act as a vasoconstrictor or steroid, which makes it suitable for long-term use in allergic eye conditions.

Patif Eye Drop is commonly used in seasonal allergic conjunctivitis, which occurs during certain times of the year, and perennial allergic conjunctivitis, which persists throughout the year due to continuous exposure to indoor allergens. It helps reduce ocular itching, irritation, mucous discharge, and conjunctival redness. Because pemirolast acts at the level of immune modulation rather than simply relieving symptoms, it is considered effective for both immediate and long-term management of ocular allergies.

In terms of mechanism of action, pemirolast interferes with calcium influx inside mast cells. Calcium signaling plays a fundamental role in the activation and degranulation of mast cells. By blocking this pathway, the drug prevents the chain reaction that leads to the release of inflammatory mediators. This stabilizing effect helps maintain cellular balance within the conjunctiva, reducing allergic responses even before symptoms fully develop.

Pharmacokinetics of pemirolast potassium show that the drug exhibits localized action when administered into the eye. Systemic absorption is minimal due to topical application. After instillation, pemirolast distributes across the conjunctival tissues and exerts its effect at the site of inflammation. It is eliminated gradually through normal tear drainage and metabolic pathways.

The formulation of Patif Eye Drop is an isotonic, sterile aqueous solution suitable for ocular application. It is typically clear and colorless, preserved with an antimicrobial agent to ensure stability and sterility throughout its shelf life. The bottle is usually made of low-density polyethylene (LDPE) with a built-in dropper tip for easy and controlled instillation.

Common side effects associated with Patif Eye Drops can include mild transient irritation, burning, stinging, watery eyes, or a temporary blurring of vision immediately after instillation. Some individuals may experience sensitivity to preservatives used in the formulation. These effects are generally short-lived and resolve as the eye adjusts to the medication. Rarely, redness or allergic reactions may occur in sensitive individuals.

Patif Eye Drop is typically packaged in a sterile multi-dose bottle and stored at room temperature, protected from light and contamination. The design ensures ease of use and helps maintain solution stability during the entire usage period.